Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $3.4 million.

  • Xeris Biopharma Holdings' Other Non-Current Liabilities fell 6031.82% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 6031.82%. This contributed to the annual value of $2.0 million for FY2024, which is 5942.66% down from last year.
  • Xeris Biopharma Holdings' Other Non-Current Liabilities amounted to $3.4 million in Q3 2025, which was down 6031.82% from $7.8 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Other Non-Current Liabilities' 5-year high stood at $30.2 million during Q2 2022, with a 5-year trough of $1.9 million in Q3 2021.
  • Its 5-year average for Other Non-Current Liabilities is $11.9 million, with a median of $7.7 million in 2024.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 148671.59% in 2022, then plummeted by 8305.98% in 2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Other Non-Current Liabilities (Quarter) stood at $22.5 million in 2021, then rose by 14.01% to $25.7 million in 2022, then plummeted by 81.13% to $4.8 million in 2023, then tumbled by 59.43% to $2.0 million in 2024, then skyrocketed by 72.45% to $3.4 million in 2025.
  • Its Other Non-Current Liabilities was $3.4 million in Q3 2025, compared to $7.8 million in Q2 2025 and $4.8 million in Q1 2025.